Assessing Regeneron Pharmaceuticals: Insights From 16 Financial Analysts
Portfolio Pulse from Benzinga Insights
Regeneron Pharmaceuticals (NASDAQ:REGN) was analyzed by 16 financial analysts, showing a mix of bullish to bearish sentiments. The average 12-month price target for REGN is $1046.81, up 1.92% from the previous target. Analyst actions include maintaining, raising, and announcing ratings with price targets ranging from $720 to $1189. Regeneron's financial performance shows a revenue growth rate of 0.58% and a net margin of 33.77%, but it lags in ROE and ROA compared to industry benchmarks. The company's debt-to-equity ratio is 0.1, indicating prudent financial management.
May 03, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron Pharmaceuticals has a mixed outlook from analysts, with an updated average price target suggesting optimism. Financial indicators show growth but highlight areas for improvement in efficiency and profitability.
The mixed analyst ratings with a slight increase in the average price target suggest a cautiously optimistic outlook for REGN. The financial performance indicates growth, but the comparison with industry benchmarks on ROE and ROA points to areas needing improvement. The prudent debt management is a positive sign. Overall, these factors combined with the company's strategic partnerships and product pipeline present a potential for short-term positive impact on REGN's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100